Page last updated at 18:21 GMT, Tuesday, 5 January 2010

Research finds no proof that a virus is the cause of ME

By Michelle Roberts
Health reporter, BBC News

Lab blood testing
The blood samples were free of XMRV

UK scientists say they can find no proof that a particular virus is the cause of chronic fatigue syndrome (CFS) or ME, contrary to recent claims.

The Imperial College London team say they want to share the findings as some patients are pinning their hopes on drugs to fight the virus called XMRV.

They analysed blood samples from 186 patients with CFS and found none had the virus, PLoS One journal reports.

Experts said the latest findings would be a bitter disappointment to many.

They said more trials were under way and when these report in coming months, scientists will be able to draw more firm conclusions.

Work in the US, published in Science, had found the retrovirus in 68 of 101 CFS patients.

The UK team say the conflict between the two studies might be down to differences between the patients enrolled or the way the research was conducted.

We need to be extremely cautious until we know more
Dr Charles Shepherd
The ME Association

Or there might be different geographical types or strains of XMRV.

Regardless, they say potent antiretroviral drugs should not be used to treat CFS because there is not enough evidence that this is necessary or helpful.

The drugs may do more harm than good, they say.

Professor Myra McClure, one of the Imperial College London investigators, said: "We are confident that our results show there is no link between XMRV and chronic fatigue syndrome, at least in the UK."

She said they had used extremely sensitive DNA testing methods, called polymerase chain reaction, to look for the virus.

"If it had been there, we would have found it."

'Disappointing'

Co-author Professor Simon Wessely said the findings did not invalidate all previous research, some of which has shown that CFS can be triggered by other infectious agents, such as Epstein Barr Virus.

ME FACTS
Causes chronic fatigue and muscle pain
Impairs immune system
Does not improve with sleep
Affects more women than men
Some have doubted it is a genuine physical illness - but the medical profession is now convinced

The charity Action for ME said it was disappointing to hear about these findings, but said no single small-scale study could be conclusive.

Dr Charles Shepherd, of The ME Association, said it was important to remain open-minded.

"We need to be extremely cautious until we know more. There has been enormous interest in this from patients.

"Some have been led into believing the cause and a test has been discovered and that treatment is just round the corner and that is not the case.

"Over the next few weeks and months we will have more results and then we can come to a conclusion.

"If it turns out that XMRV is important, we will have to start looking at whether it is worthwhile testing for it and treating it."

The team behind the initial US study said the latest work did not use the same "rigorous" techniques they had used and therefore the results were not comparable.

Dr Judy Mikovits from the Whittemore Peterson Institute said: "Little is known about the prevalence of XMRV worldwide, much less the incidence of XMRV in ME/CFS or prostate cancer.

She added more study was needed and they were collaborating with international research teams to unpick the questions around the virus.

In a statement, the charity Invest in ME said the original Science study was of the "highest quality", and that much more work was required before any firm conclusions could be drawn.



Print Sponsor


SEE ALSO
ME virus discovery raises hopes
09 Oct 09 |  Health
Stress hormone 'a marker for ME'
06 Jan 09 |  Health
Myalgic encephalomyelitis
24 Oct 08 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

PRODUCTS & SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific